WallStSmart

Danaher Corporation (DHR)vsFresh2 Group Ltd (FRES)

VS

Smart Verdict

WallStSmart Research — data-driven comparison

Danaher Corporation generates 144588% more annual revenue ($24.57B vs $16.98M). DHR leads profitability with a 14.7% profit margin vs 0.0%. DHR earns a higher WallStSmart Score of 60/100 (C).

DHR

Buy

60

out of 100

Grade: C

Growth: 4.0Profit: 6.0Value: 7.3Quality: 6.3
Piotroski: 4/9Altman Z: 2.36

FRES

Avoid

33

out of 100

Grade: F

Growth: 3.3Profit: 2.5Value: 5.0Quality: 5.0
IV

Intrinsic Value Comparison

Multi-model valuation · Graham Formula

DHRSignificantly Overvalued (-38.6%)

Margin of Safety

-38.6%

Fair Value

$135.07

Current Price

$187.15

$52.08 premium

UndervaluedFair: $135.07Overvalued

Intrinsic value data unavailable for FRES.

Key Strengths & Concerns

Side-by-side fundamental analysis

Key Strengths

DHR4 strengths · Avg: 8.3/10
Market CapQuality
$134.43B9/10

Large-cap with strong market position

Price/BookValuation
2.5x8/10

Reasonable price relative to book value

Operating MarginProfitability
22.2%8/10

Strong operational efficiency at 22.2%

Free Cash FlowQuality
$1.75B8/10

Generating 1.7B in free cash flow

FRES1 strengths · Avg: 10.0/10
Price/BookValuation
0.0x10/10

Reasonable price relative to book value

Areas to Watch

DHR3 concerns · Avg: 3.7/10
P/E RatioValuation
37.7x4/10

Premium valuation, high expectations priced in

Revenue GrowthGrowth
4.6%4/10

4.6% revenue growth

Return on EquityProfitability
7.0%3/10

ROE of 7.0% — below average capital efficiency

FRES4 concerns · Avg: 3.0/10
EPS GrowthGrowth
0.0%4/10

0.0% earnings growth

Market CapQuality
$2.97M3/10

Smaller company, higher risk/reward

Profit MarginProfitability
0.0%3/10

0.0% margin — thin

Return on EquityProfitability
-2.2%2/10

ROE of -2.2% — below average capital efficiency

Comparative Analysis Report

WallStSmart Research

Bull Case : DHR

The strongest argument for DHR centers on Market Cap, Price/Book, Operating Margin. PEG of 1.23 suggests the stock is reasonably priced for its growth.

Bull Case : FRES

The strongest argument for FRES centers on Price/Book.

Bear Case : DHR

The primary concerns for DHR are P/E Ratio, Revenue Growth, Return on Equity.

Bear Case : FRES

The primary concerns for FRES are EPS Growth, Market Cap, Profit Margin.

Key Dynamics to Monitor

FRES carries more volatility with a beta of 1.28 — expect wider price swings.

DHR is growing revenue faster at 4.6% — sustainability is the question.

Monitor DIAGNOSTICS & RESEARCH industry trends, competitive dynamics, and regulatory changes.

Bottom Line

DHR scores higher overall (60/100 vs 33/100). Both earn "Buy" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.

This analysis is generated from publicly available financial data. Not financial advice.

Danaher Corporation

HEALTHCARE · DIAGNOSTICS & RESEARCH · USA

Danaher Corporation is an American globally diversified conglomerate with its headquarters in Washington, D.C.. The company designs, manufactures, and markets professional, medical, industrial, and commercial products and services. The company's 3 platforms are Life Sciences, Diagnostics, and Environmental & Applied Solutions.

Fresh2 Group Ltd

HEALTHCARE · DIAGNOSTICS & RESEARCH · USA

Fresh2 Group Limited, a biotechnology company, researches, develops, markets, and sells multi-cancer screening and detection tests using cancer differentiation analysis technology and device to corporations and life insurance companies in the People's Republic of China. The company is headquartered in New York, New York.

Want to dig deeper into these stocks?